FlandersBio on Twitter

Follow us on Twitter

Archive for October 2010 - News

Archive for October 2010 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Galapagos receives €3.7 million grant for cystic fibrosis program

28.10.2010

Galapagos NV (Euronext: GLPG) announces today that it has been awarded a €3.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT). read more

ThromboGenics Raises € 2.8 Million from the Exercise of Warrants

27.10.2010

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has raised € 2.8 million as the result of the exercise of warrants by a number of the Company’s employees. The 289,000 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this transaction, ThromboGenics now has 29,445,234 shares outstanding. read more

Galapagos completes private placement by issuance of 2,389,347 new ordinary shares

22.10.2010

Galapagos NV (Euronext: GLPG) announces that it has completed its capital increase by issuing today 2,389,347 new ordinary shares. These shares will be delivered to Belgian and international institutional and other eligible investors who participated in the €28.7 million private placement closed earlier this week. The newly issued shares will be admitted to listing on NYSE Euronext Brussels/Amsterdam on 25 October 2010. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print